IAS 2024: Open letter to IAS over online access
1 September 2024. Related: Editorial, Conference reports.
World AIDS 25 Munich 2024
AIDS 2024: Ten early reports
12 August 2024. Related: Conference reports, Antiretrovirals.
Five days on two days off: Biktarvy in pilot FOTO study
12 August 2024. Related: Conference reports, Antiretrovirals.
Subcutaneous formulation of long-acting CAB/RPV discontinued
10 August 2024. Related: Conference reports, Antiretrovirals.
First data on third-generation integrase inhibitor from ViiV
10 August 2024. Related: Conference reports, Antiretrovirals.
Switching to daily oral bictegravir and lenacapavir dual therapy to simplify ART in ARTISTRY-1 study
10 August 2024. Related: Conference reports, Antiretrovirals.
AIDS 2024: Lenacapavir as PrEP is “beyond wonderful” but PURPOSE 1 study tells us so much more
29 July 2024. Related: Conference reports, HIV prevention and transmission.
Lenacapavir could be produced for $40 a year: 1000-fold lower than current US price for treating MDR HIV
26 July 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
AIDS 2024: Introduction to AIDS 2024
22 July 2024. Related: Conference reports.
UNAIDS report: The urgency of now – AIDS at a crossroads.
22 July 2024. Related: Conference reports, Treatment advocacy.
New community call to challenge social settings that drive HIV-related stigma
20 July 2024. Related: Conference reports, HIV prevention and transmission, Treatment advocacy.
HIV research to watch out for at the AIDS 2024 conference
18 July 2024. Related: Conference reports.